Pharmaceuticals - Community Register


Community register of veterinary medicinal products


Product information

Invented name: Semintra   
Auth. number : EU/2/12/146
Active substance : Telmisartan
ATC: Anatomical main group: QC - Cardiovascular system
Therapeutic subgroup: QC09 - Agents acting on the renin-angiotensin system
Pharmacological subgroup: QC09C - Angiotensin II antagonists, plain
Chemical subgroup: QC09CA - Angiotensin II antagonists, plain
Chemical substance: QC09CA07 - telmisartan
(See WHO ATCvet Index)
Indication: Reduction of proteinuria associated with chronic kidney disease (CKD) in cats.
Marketing Authorisation Holder: Boehringer Ingelheim Vetmedica GmbH
D-55216 Ingelheim am Rhein, Deutschland
EPAR and active package presentations

Package presentations

Information about presentations can be found in the website of the European Medicines Agency under the section "Product Information".
Likewise, presentations on which there has been a Commission decision are referred in the Summary of Product Characteristics (Annex I to the Commission Decision granting the marketing authorisation) which is available in the Community Register.

European Commission proceduresGoto top of the page

Close date procedure Procedure type EMEA number Decision summary publ decision docs annex
15/02/2013 Centralised - Authorisation EMEA/V/C/2436 (2013)932 of 13/02/2013
12/12/2013 Centralised - Variation EMEA/V/C/2436/IA/1
Updated with Decision(2014)9273 of 28/11/2014
02/12/2014 Centralised - Yearly update (2014)9273 of 28/11/2014
06/11/2015 Centralised - Variation EMEA/V/C/2436/IB/4/G
Updated with Decision(2016)7294 of 09/11/2016
27/09/2016 Centralised - Variation EMEA/V/C/2436/IG/722
Updated with Decision(2016)7294 of 09/11/2016
11/11/2016 Centralised - Yearly update (2016)7294 of 09/11/2016
20/12/2016 Corrigendum (2016)7294 of 09/11/2016
18/01/2018 Centralised - Renewal EMEA/V/C/2436/R/9 (2018)291 of 16/01/2018